Home Cart Sign in  
Chemical Structure| 55290-63-6 Chemical Structure| 55290-63-6

Structure of Atractylodin
CAS No.: 55290-63-6

Chemical Structure| 55290-63-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Atractylodin is an active component of the essential oil contained in the rhizomes of Atractylodes lancea and A.

Synonyms: Atractydin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Atractylodin

CAS No. :55290-63-6
Formula : C13H10O
M.W : 182.22
SMILES Code : C/C=C/C#CC#C/C=C/C1=CC=CO1
Synonyms :
Atractydin
MDL No. :MFCD01075143
InChI Key :GRBKWAXRYIITKG-QFMFQGICSA-N
Pubchem ID :5321047

Safety of Atractylodin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Atractylodin

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT116 cells 50 μM 24 h Determine the non-cytotoxic concentration of Atractylodin Int J Mol Sci. 2023 Jan 2;24(1):802
HCT116 cells 50 μM 1 hour Investigate the inhibitory effect of Atractylodin on TNF-α-induced NF-κB p65 phosphorylation Int J Mol Sci. 2023 Jan 2;24(1):802
rat dorsal root ganglion neurons 5 µM 30 s ATR induced a long-lasting calcium response, persisting for over 1 h Int J Mol Sci. 2021 Mar 31;22(7):3614
hTRPA1-transfected HEK293 cells 10 µM 1 min ATR induced long-lasting TRPA1 channel activation, persisting beyond 3 min after washout Int J Mol Sci. 2021 Mar 31;22(7):3614
A549 cells 0-100 μM 24 h To evaluate the effect of Atractylodin on TGF-β1-induced EMT in A549 cells, results showed that Atractylodin suppressed EMT-related protein expressions. Int J Mol Sci. 2021 Oct 15;22(20):11152
RAW264.7 cells 10, 20, 40 μM 24 h To investigate the inhibitory effect of Atractylodin on LPS-induced inflammatory response in macrophages. Results showed that Atractylodin significantly inhibited the mRNA expression of TNF-α, IL-1β, IL-6, and iNOS, and downregulated the phosphorylation levels of MAPK pathway proteins. Front Pharmacol. 2021 Jul 15;12:665376
HCC827 lung cancer cells 61.05 μM 24 h Cell viability was detected by the Cell Counting Kit-8 assay, and results showed that ATR could significantly inhibit the proliferation of HCC827 cells Molecules. 2022 May 5;27(9):2946
NCI-H460 lung cancer cells 63.27 μM 24 h Cell viability was detected by the Cell Counting Kit-8 assay, and results showed that ATR could significantly inhibit the proliferation of NCI-H460 cells Molecules. 2022 May 5;27(9):2946
NCI-H23 lung cancer cells 76.88 μM 24 h Cell viability was detected by the Cell Counting Kit-8 assay, and results showed that ATR could significantly inhibit the proliferation of NCI-H23 cells Molecules. 2022 May 5;27(9):2946
A549 lung cancer cells 37.92 μM 24 h Cell viability was detected by the Cell Counting Kit-8 assay, and results showed that ATR could significantly inhibit the proliferation of A549 cells Molecules. 2022 May 5;27(9):2946

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male SD rats LPS-induced acute lung injury model Gavage 10 mg/kg, 40 mg/kg Once daily for 7 days To evaluate the therapeutic effects of ATL on acute lung injury. Results showed that ATL significantly reduced the lung wet/dry ratio, improved pathological changes, and lowered the expression levels of inflammatory factors TNF-α, IL-1β, IL-6, COX-2, and iNOS, as well as reduced neutrophil and macrophage aggregation. iScience. 2024 Aug 31;27(10):110751
C57BL/6 mice DSS-induced colitis model Intraperitoneal injection 40 mg/kg Once daily for 14 days Investigate the ameliorative effect of Atractylodin on colitis symptoms Int J Mol Sci. 2023 Jan 2;24(1):802
Rats Nociceptive behavior model Intraperitoneal injection 5 mg/kg Single injection, assessed after 20 min Systemic ATR application dose-dependently inhibited AITC-induced nociceptive behaviors Int J Mol Sci. 2021 Mar 31;22(7):3614
C57B/6 male mice Bleomycin-induced pulmonary fibrosis model Intraperitoneal injection 50 or 100 mg/kg Once daily for 20 consecutive days To evaluate the therapeutic effect of Atractylodin on bleomycin-induced pulmonary fibrosis, results showed that Atractylodin attenuated pulmonary fibrosis and reduced collagen deposition. Int J Mol Sci. 2021 Oct 15;22(20):11152
Mice Klotho-deficient and SAMP8 mice Oral 1 mg/kg Daily administration Atractylodin significantly prolonged the survival of klotho-deficient mice, ameliorated several age-related diseases, and reduced microglial activation in the brain Mol Psychiatry. 2016 Nov;21(11):1613-1623
Wistar rats AH-130 ascites hepatoma tumor-bearing rats Oral 1 mg/kg Daily administration Atractylodin significantly prolonged the median survival time of tumor-bearing rats. Transl Psychiatry. 2011 Jul 26;1(7):e23
BALB/c mice DSS-induced ulcerative colitis model Intraperitoneal injection 10 or 20 mg/kg Once daily for 7 days To evaluate the therapeutic effects of Atractylodin on DSS-induced ulcerative colitis. Results showed that Atractylodin significantly improved symptoms such as weight loss, disease activity index score, and colon length shortening, and inhibited macrophage activation and inflammatory cytokine production in colon tissues. Front Pharmacol. 2021 Jul 15;12:665376

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.49mL

1.10mL

0.55mL

27.44mL

5.49mL

2.74mL

54.88mL

10.98mL

5.49mL

References

 

Historical Records

Categories